Fig. 6. (A) Cell viabilities of U87MG cells after CuS-apoferritin (100 μg mL⁻¹) and CuS-apoferritin-MBA (100 μg mL⁻¹) induced photothermal ablation at different laser power densities (0.2, 0.5, 0.8, and 1.0 W cm⁻²). (B) Cell viabilities of U87MG cells incubated with different concentrations (10, 20, 40, 80, and 100 μg mL⁻¹) of CuS-apoferritin and CuS-apoferritin-MBA under exposure to the 808 nm laser at a power density of 1 W cm⁻². (C) Cell viabilities of U87MG cells after CuS-apoferritin (100 μg mL⁻¹) and CuS-apoferritin-MBA (100 μg mL⁻¹) with anti-TfR induced photothermal ablation at different laser power densities (0.2, 0.5, 0.8, and 1.0 W cm⁻²). (D) Cell viabilities of U87MG cells incubated with different concentrations (10, 20, 40, 80, and 100 μg mL⁻¹) of CuS-apoferritin and CuS-apoferritin-MBA under exposure to the 808 nm laser at the a power density of 1 W cm⁻². (E) Confocal fluorescence images of Calcein AM/PI co-stained U87MG cells incubated with CuS-apoferritin (100 μg mL⁻¹) and CuS-apoferritin-MBA (100 μg mL⁻¹) after being exposed to the 808 nm laser (1 W cm⁻²) for 5 min. Error bar is 20 μm.